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after	 transplantation.	A	more	precise	 indication	which	patients	could	benefit	 from	
reinduction	therapy	is	warranted.
Methods: We	retrospectively	analyzed	outcomes	of	83	patients	with	postallogeneic	









Conclusion: We	 confirmed	 the	 dismal	 prognosis	 of	 postallogeneic	 HSCT	 relapse.	
Importantly,	 our	 data	 demonstrate	 that	 patients	 fit	 enough	 to	 receive	 high‐dose	
chemotherapy,	 even	 when	 relapse	 occurred	 <6	 months,	 had	 the	 best	 chance	 to	
obtain	 durable	 remissions,	 in	 particular	when	 immunologic	 consolidation	was	 per‐
formed	after	reaching	CR.



















































allogeneic	HSCT,	depending	on	 the	 type	of	 the	donor	and	disease	
status	 at	 transplant.1,2	 Prognosis	 of	 postallogeneic	HSCT	AML	 re‐
lapse	is	poor3,4	and	has	hardly	improved	in	the	past	decades.	There	is	
no	standard	of	care	for	patients	who	relapse	after	allogeneic	HSCT.	


















augmenting	 GvL	 responses.	 In	 a	 small	 group	 of	 patients	 with	 AML	
or	MDS	relapse	after	allogeneic	HSCT,	azacitidine	 induced	complete	
remission,	and	about	50%	of	these	patients	had	prolonged	(>2	years)	
disease‐free	survival.12	 If	 the	clinical	condition	of	 the	patient	allows,	
high‐dose	 chemotherapy	 can	 be	 tried	 in	 order	 to	 achieve	 complete	
remission.1,13	The	decision	of	physician	and	patient	to	treat	or	refrain	

















with	 postallogeneic	 HSCT	 AML	 relapse,	 in	 whom	 the	 decision	 to	
offer	curative	or	best	supportive	care	therapy	was	based	on	factors	
described	above,	 a	per‐patient	 analysis	of	physical	 fitness	 and	co‐
morbidity,	and	individual	considerations	of	the	patient.
2  | PATIENTS AND METHODS
2.1 | Patients
The	medical	 records	of	 all	 83	 adult	 patients	 (>17	years	of	 age)	with	
myeloid	 malignancies	 who	 had	 received	 an	 allogeneic	 HSCT	 at	 the	
























The	 collected	 data	 were	 coded	 and	 anonymously	 processed.	 The	
analyses	 were	 done	 using	 IBM	 SPSS	 Statistics	 24.0.0.1	 software.	
Patient	characteristics	were	compared	using	Mann‐Whitney	U	tests	
in	 case	 of	 continuous	 variable,	 and	 the	 chi‐square	 test	 or	 Fisher's	
exact	 test	were	used	to	compare	categorical	variables.	For	 the	or‐





Demographics	 of	 the	 83	 patients	who	 had	 received	 an	 allogeneic	
HSCT	 for	 AML	 or	 high‐risk	 MDS	 between	 January	 1,	 2010	 and	
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December	31,	2016,	and	 relapsed	before	December	31,	2017,	are	
shown	 in	Table	1.	Three	patients	 (4%)	who	had	been	 initially	clas‐
sified	 as	 good	 risk	 had	 received	 an	 allogeneic	 HSCT	 because	 of	
relapsed	AML.	Four	of	the	patients	had	an	intracranial	or	leptome‐
ningeal	localization	of	their	relapse,	and	no	AML	blasts	in	the	bone	
marrow.	 Median	 time	 of	 follow‐up	 for	 survivors	 was	 220	 weeks,	
ranging	from	49	to	391	weeks.
3.2 | Curative treatment vs best supportive care
Patients	were	classified	into	two	groups:	patients	who	were	treated	
with	curative	intent	(CIT	group)	and	patients	who	refrained	from	cu‐
rative	 treatment	 and	 received	best	 supportive	 care	 either	 at	 their	
own	 request	 or	 as	 advised	 by	 the	 treating	 physician	 (BSC	 group).	
Treatment	with	 curative	 intent	was	 considered	 in	 all	 patients	 that	
were	 fit	 enough	 according	 to	 the	 treating	 physician,	 in	 particular	
when	relapse	occurred	more	than	6	months	after	allogeneic	HSCT.	
Despite	 the	 fact	 that	 relapse	 less	 than	 6	months	 after	 allogeneic	
HSCT	is	considered	a	very	poor	prognostic	factor,	11	patients	with	
such	an	early	 relapse	 received	 reinduction	 chemotherapy,	 in	most	
cases	 because	of	 young	 age,	 excellent	 clinical	 condition,	 and	 very	








lower	 bone	marrow	 blast	 counts	 (median	 21%	 vs	 38%,	P	 =	 .025),	
and	had	lower	cytogenetical/molecular	risk	characteristics	(r	=	.226;	
P	=	.040;	Table	2).	When	excluding	the	relapses	that	were	restricted	
to	 the	 central	 nervous	 system,	 no	 significant	 difference	 in	 bone	
marrow	blast	count	was	observed	between	the	BSC	and	CIT	groups	
(median	38%	vs	24%,	P	=	.082).	No	differences	could	be	assessed	for	














FLAG	 (fludarabine,	 cytarabine,	 G‐CSF)	 or	 other	 regimens	 in	 the	
other	patients	(Table	S2).	Four	patients	had	an	isolated	central	ner‐
vous	 system	 relapse	with	 intracranial	 chloroma	or	 leptomeningeal	
AML	localization.	These	patients	were	in	the	CIT	group	and	received	
TA B L E  1  Patient	characteristics
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TA B L E  2  Patient	characteristics	of	best	supportive	care	and	curative‐intent	groups
Characteristic Curative (n = 50)
Best supportive care 
(n = 33)  
Outcome—no.	(%)
Deceased 37	(74) 33	(100)  
Survived 13	(26) 0	(0)
Sex—no.	(%)
Male 29	(58) 17	(48.5) P	=	.561
Female 21	(42) 16	(51.5)
Age	at	time	of	allogeneic	HSCT—y
Median	(interquartile	range) 53	(39‐58) 58	(50‐64) P = .043
Range 18‐71 26‐68
Prognostic	class	at	time	of	AML	diagnosis—no.	(%)





















Myeloablative 7	(14) 1	(3) P = .137
Reduced	intensity	or	FLAMSA 43	(86) 32	(97)
Bone	marrow	blast	count	at	time	of	relapse—%	(n	=	74)
Median	(interquartile	range) 21	(10‐50) 38	(20‐67) P	=	.025† 
Range 0‐74 10‐99
No	data 4 5  
Time	between	allogeneic	HSCT	and	relapse—wk
Median	(interquartile	range) 21	(14‐47) 21	(6‐28) P = .047
Range 5‐187 3‐63
Early	vs	late	relapse—no.	(%)
Early	(<3	mo) 11	(22) 12	(36) P = .119
Late	(≥3	mo) 39	(78) 21	(64)
Time	between	relapse	and	death—wk
Median	(interquartile	range) 16	(6‐31) 3	(1‐10) P	<	.001
Range 2‐119 0‐37
†When	n	=	4	patients	with	isolated	CNS	relapse	are	excluded,	the	difference	in	bone	marrow	blast	counts	between	the	two	groups	is	not	significant.	
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intrathecal	cytarabine,	in	some	combined	with	systemic	cytarabine,	












patient,	AML	 relapsed	 after	 she	 had	 obtained	 complete	 remission	
following	reinduction	 therapy	with	curative	 intent	 (tapering	of	 im‐
munosuppressants	followed	by	hypomethylating	therapy).	This	pa‐
tient	was	still	alive	but	with	active	AML	at	the	end	of	follow‐up	and	
therefore	evaluated	in	the	survivor	group	(Table	S2, patient ID_030). 
There	was	no	difference	in	age,	type	of	transplantation,	condition‐
ing	regimen,	bone	marrow	blast	percentage	at	time	of	relapse	or	the	
time	between	 transplantation,	 and	 relapse	between	 survivors	 and	
non‐survivors.	 However,	 survivors	 had	more	 often	 received	 high‐
dose	reinduction	chemotherapy	(69%	vs	35%,	P	=	.035)	and	immu‐
nologic	 consolidation	 therapy	 (69%	 vs	 22%,	P	 =	 .003;	 Table	 3).	 In	
addition,	survivors	had	more	often	reached	complete	remission	after	
F I G U R E  1  Overall	survival.	Survival	curve	of	the	entire	patient	
cohort	(n	=	83).	One‐year	survival	was	23%,	and	2‐y	survival	was	
17%
















DLI,	 one	 patient	 second	 allogeneic	 HSCT),	 despite	 not	 obtaining	
complete	 remission,	 and	 two	of	 them	 survived	 (one	who	 received	
DLI	and	the	patient	who	received	2nd	allogeneic	HSCT).	Estimated	
median	survival	time	of	patients	who	did	not	reach	complete	remis‐




HSCT	 (P	 =	 .004;	 Figure	 3B).	When	 relapse	within	 6	months	 after	
TA B L E  3  Patient	characteristics	of	survivors	and	non‐survivors	in	the	curative‐intent	group
Characteristic Non‐survivors (n = 37) Survivors (n = 13)  
Sex—no.	(%)
Male 21	(57) 8	(62) P	=	.764
Female 16	(43) 5	(39)
Age	at	time	of	allogeneic	HSCT—y
Median	(interquartile	range) 53	(39‐60) 53	(36‐59) P	=	.674
Range 18‐71 22‐62
Age	at	time	of	relapse—y
Median	(interquartile	range) 53	(40‐60) 53	(38‐60) P = .707
Range 19‐74 22‐62
Bone	marrow	blast	count	at	time	of	relapse—%	(n	=	46)
Median	(interquartile	range) 20	(14‐51) 22	(8‐49) P	=	.745
Range 1‐72 0‐74
No	data 3 1  
Reinduction	therapy—no.	(%)





No/low‐intensity	therapy 24	(65) 4	(31) P	=	.035
High‐intensity 13	(35) 9	(69)
Outcome	after	reinduction	therapy—no.	(%)
CR 11	(30) 11	(85) P = .001
No	CR 26	(70) 2	(15)
Hypomethylating	agents—no.	(%)
Yes 7	(19) 3	(23) P	=	.533
No 29	(81) 10	(77)
No	data 1   
Consolidation	therapy
No	consolidation	therapy 29	(78) 4	(31) P = .003
Consolidation	therapy 8	(22) 9† 	(69)
Time	between	HSCT	and	relapse—wk
Median	(interquartile	range) 21	(12‐46) 21	(17‐59) P = .479
Range 5‐142 11‐187
Early	vs	late	relapse—no.	(%)
Early	(<3	mo) 10	(27) 1	(8) P = .144
Late	(≥3	mo) 27	(73) 12	(92)
†Two	received	a	second	allogeneic	HSCT	with	a	different	donor,	the	other	patients	DLI.	
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dismal	prognosis.	 It	 remains	 a	 challenge	 to	 identify	 those	patients	










a	 non‐preselected	 patient	 group	with	 relapse	 of	AML	or	 high‐risk	
MDS	after	allogeneic	HSCT,	we	attempted	to	 identify	 factors	 that	




















confident	 that	 the	patients	 that	we	qualified	as	non‐relapse	survi‐
vors	are	likely	to	be	cured.
Previous	analyses	on	survival	after	relapse	focused	on	patients	
treated	 with	 curative	 intent	 only,	 inherently	 containing	 the	 risk	
of	 selection	 bias.	 In	 our	 study,	 we	 included	 all	 patients	 with	 re‐
lapsed	AML	or	high‐risk	MDS	after	allogeneic	HSCT	in	our	center.	
Comparison	of	the	CIT	and	BSC	groups,	defined	based	on	intention	





not	 significantly	 different	 between	 survivors	 and	 non‐survivors	
of	 patients	 treated	with	 curative	 intent,	while	 the	 curative‐intent	
group	had	a	higher	age	 range.	Blast	 count	at	diagnosis	of	 relapse	
was	not	 significantly	 associated	with	outcome	within	 the	CIT	pa‐
tient	group,	and	due	to	the	size	of	the	patient	group,	we	could	not	












tients	 in	our	 study.	The	majority	of	patients	 received	 reduced‐in‐
tensity	conditioning	(RIC).	Nevertheless,	survivor	and	non‐survivor	
groups	in	our	analysis	both	contained	young	and	old	patients,	with	
low	 and	 higher	 amounts	 of	 bone	marrow	 blasts.	 Together,	 these	
data	 suggest	 that	 fitness	 rather	 than	 age,	 blast	 count,	 or	 time	 of	
relapse	(except	when	<3	months	after	allogeneic	HSCT)	should	be	
taken	 into	 account	when	 considering	 patients	 for	 remission	 rein‐
duction	therapy.
We	 confirm	 previous	 reports	 demonstrating	 that	 re‐ob‐
taining	 complete	 remission	 is	 an	 important	 prognostic	 determi‐
nant.3,4,20‐22,24	Only	2	of	the	28	patients	that	did	not	reach	complete	





subsequent	 hypomethylating	 agents	 or	 high‐dose	 chemotherapy)	
led	to	remission	of	AML	in	5	out	of	18	patients	(28%).	Cessation	of	
immunosuppressants	 in	combination	with	hypomethylating	agents	
led	 to	CR	 in	 two	out	of	 five	patients.	None	of	 the	 five	 remaining	
patients	receiving	hypomethylating	therapy	(stand‐alone	or	in	com‐
bination	with	other	therapies)	obtained	complete	remission.	These	
results	are	 in	 line	with	 the	15%‐19%	complete	 remission	 rates	 re‐











Equally	 important	 and	 challenging	 is	 the	maintenance	 of	 com‐
plete	 remission.	Of	 the	 12	 patients	who	 after	 obtaining	 complete	
remission	 received	 immunological	 consolidation,	 most	 often	 DLI,	
and	 in	 one	 case	 second	 allogeneic	HSCT,	 seven	 patients	 survived	
(58%).	 In	contrast,	only	30%	of	the	patients	who	reached	CR,	but,	
due	to	varying	reasons,	could	not	proceed	to	 immunologic	consol‐
idation,	 survived	 (Figure	 2).	 AML	 relapse	 after	 allogeneic	HSCT	 is	
associated	with	a	dysregulation	in	immune	function	pathways	such	
as	HLA	expression	by	AML	blasts	 that	may	help	AML	 cells	 evade	
donor	 immune	 responses.27	 Immunologic	 consolidation	 can	be	 ef‐
fective	when	newly	infused	donor	immune	cells	that	are	naive	with	
regard	 to	 the	 patient's	AML	elicit	 a	GvL	 response	 independent	 of	
HLA‐related	antigen	presentation,	 for	example,	 to	 targets	 that	are	
expressed	on	the	membrane	of	AML	blasts.28,29	Thus,	as	also	sug‐
gested	 by	 other	 studies,	 immunological	 consolidation	 is	 of	 impor‐
tance	 for	 survival	 in	 this	 setting.	GvHD	occurred	 in	 some	but	not	
all	surviving	patients	suggesting	that	immunologic	consolidation	can	
also	be	effective	when	it	does	not	lead	to	GvHD.3
















of	 treating	physicians	and	on	 the	motivation	of	 the	patient.	 In	pa‐
tients	deemed	fit,	reinduction	therapy	may	offer	a	prospect	for	cure.	
Our	data	suggest	that	more	patients	might	be	eligible	for	intensive	
reinduction	 treatment	 than	 previously	 assumed	 as	 time	 between	
transplantation	 and	 relapse	 should	 only	 be	 taken	 into	 account	 in	
case	of	very	early	relapses,	for	example,	<3	months	after	allogeneic	
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